PURPOSE: Nonsteroidal antiinflammatory drugs (NSAIDs) have been shown to reduce cell growth in several tumors. Among these possible antineoplastic drugs are cyclooxygenase- 2 (COX-2)-selective drugs, such as celecoxib, in which antitumoral mechanisms were evaluated in rats bearing Walker-256 (W256) tumor. METHODS: W256 carcinosarcoma cells were inoculated subcutaneously (10(7) cells/rat) in rats submitted to treatment with celecoxib (25 mg kg(-1)) or vehicle for 14 days. Tumor growth, body-weight gain, and survival data were evaluated. The mechanisms, such as COX-2 expression and activity, oxidative stress, by means of enzymes and lipoperoxidation levels, and apoptosis mediators were also investigated. RESULTS: A reduction in tumor growth and an increased weight gain were observed. Celecoxib provided a higher incidence of survival compared with the control group. Cellular effects are probably COX-2 independent, because neither enzyme expression nor its activity, measured by tumoral PGE(2), showed significant difference between groups. It is probable that this antitumor action is dependent on an apoptotic way, which has been evaluated by the expression of the antiapoptotic protein Bcl-xL, in addition to the cellular changes observed by electronic microscopy. Celecoxib has also a possible involvement with redox homeostasis, because its administration caused significant changes in the activity of oxidative enzymes, such as catalase and superoxide dismutase. CONCLUSION: These results confirm the antitumor effects of celecoxib in W256 cancer model, contributing to elucidating its antitumoral mechanism and corroborating scientific literature about its effect on other types of cancer.
PURPOSE: Nonsteroidal antiinflammatory drugs (NSAIDs) have been shown to reduce cell growth in several tumors. Among these possible antineoplastic drugs are cyclooxygenase- 2 (COX-2)-selective drugs, such as celecoxib, in which antitumoral mechanisms were evaluated in rats bearing Walker-256 (W256) tumor. METHODS: W256 carcinosarcoma cells were inoculated subcutaneously (10(7) cells/rat) in rats submitted to treatment with celecoxib (25 mg kg(-1)) or vehicle for 14 days. Tumor growth, body-weight gain, and survival data were evaluated. The mechanisms, such as COX-2 expression and activity, oxidative stress, by means of enzymes and lipoperoxidation levels, and apoptosis mediators were also investigated. RESULTS: A reduction in tumor growth and an increased weight gain were observed. Celecoxib provided a higher incidence of survival compared with the control group. Cellular effects are probably COX-2 independent, because neither enzyme expression nor its activity, measured by tumoral PGE(2), showed significant difference between groups. It is probable that this antitumor action is dependent on an apoptotic way, which has been evaluated by the expression of the antiapoptotic protein Bcl-xL, in addition to the cellular changes observed by electronic microscopy. Celecoxib has also a possible involvement with redox homeostasis, because its administration caused significant changes in the activity of oxidative enzymes, such as catalase and superoxide dismutase. CONCLUSION: These results confirm the antitumor effects of celecoxib in W256 cancer model, contributing to elucidating its antitumoral mechanism and corroborating scientific literature about its effect on other types of cancer.
Authors: S Anthony Kahn; Christine M Mullin; Louis-Philippe de Lorimier; Kristine E Burgess; Rebecca E Risbon; Rogers M Fred; Kenneth Drobatz; Craig A Clifford Journal: Can Vet J Date: 2013-03 Impact factor: 1.008
Authors: Wilmarie Flores-Santana; Terry Moody; Weibin Chen; Michael J Gorczynski; Mai E Shoman; Carlos Velázquez; Angela Thetford; James B Mitchell; Murali K Cherukuri; S Bruce King; David A Wink Journal: Br J Pharmacol Date: 2012-02 Impact factor: 8.739
Authors: Camila Oliveira de Souza; Mirian Ayumi Kurauti; Flaviane de Fatima Silva; Hely de Morais; Glaucia Regina Borba-Murad; Fábio Goulart de Andrade; Helenir Medri de Souza Journal: Mol Cell Biochem Date: 2014-10-31 Impact factor: 3.396
Authors: Laurence Booth; Jane L Roberts; Nichola Cruickshanks; Seyedmehrad Tavallai; Timothy Webb; Peter Samuel; Adam Conley; Brittany Binion; Harold F Young; Andrew Poklepovic; Sarah Spiegel; Paul Dent Journal: J Cell Physiol Date: 2015-05 Impact factor: 6.384
Authors: Shahin Assefnia; Sivanesan Dakshanamurthy; Jaime M Guidry Auvil; Constanze Hampel; Panos Z Anastasiadis; Bhaskar Kallakury; Aykut Uren; David W Foley; Milton L Brown; Lawrence Shapiro; Michael Brenner; David Haigh; Stephen W Byers Journal: Oncotarget Date: 2014-03-30